ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Exact Sciences (EXAS): Buy, Sell, or Hold Post Q3 Earnings?

EXAS Cover Image

What a time it’s been for Exact Sciences. In the past six months alone, the company’s stock price has increased by a massive 152%, reaching $103.18 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Is there a buying opportunity in Exact Sciences, or does it present a risk to your portfolio? Get the full breakdown from our expert analysts, it’s free.

Why Is Exact Sciences Not Exciting?

Despite the momentum, we're swiping left on Exact Sciences for now. Here are two reasons we avoid EXAS and a stock we'd rather own.

1. Cash Burn Ignites Concerns

Free cash flow isn't a prominently featured metric in company financials and earnings releases, but we think it's telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king.

While Exact Sciences posted positive free cash flow this quarter, the broader story hasn’t been so clean. Exact Sciences’s demanding reinvestments have consumed many resources over the last five years, contributing to an average free cash flow margin of negative 2%. This means it lit $2.00 of cash on fire for every $100 in revenue.

Exact Sciences Trailing 12-Month Free Cash Flow Margin

2. Previous Growth Initiatives Have Lost Money

Growth gives us insight into a company’s long-term potential, but how capital-efficient was that growth? A company’s ROIC explains this by showing how much operating profit it makes compared to the money it has raised (debt and equity).

Exact Sciences’s five-year average ROIC was negative 13.7%, meaning management lost money while trying to expand the business. Its returns were among the worst in the healthcare sector.

Exact Sciences Trailing 12-Month Return On Invested Capital

Final Judgment

Exact Sciences isn’t a terrible business, but it doesn’t pass our bar. After the recent surge, the stock trades at 121.8× forward P/E (or $103.18 per share). This multiple tells us a lot of good news is priced in - we think there are better opportunities elsewhere. We’d suggest looking at one of our top digital advertising picks.

High-Quality Stocks for All Market Conditions

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  250.08
+10.19 (4.25%)
AAPL  258.78
-0.42 (-0.16%)
AMD  252.95
+6.12 (2.48%)
BAC  53.35
+0.00 (0.01%)
GOOG  329.76
+10.55 (3.31%)
META  663.83
+29.30 (4.62%)
MSFT  393.92
+9.55 (2.48%)
NVDA  194.62
+5.31 (2.81%)
ORCL  163.65
+8.03 (5.16%)
TSLA  366.42
+14.00 (3.97%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.